Abstract 1674P
Background
Nasopharyngeal carcinoma (NPC) can have implications on the sexual health of patients suffering from this cancer. This can be affected by various factors, whether it be the cancer itself, the treatments administered, or the associated psychological stress. However, sexual disorders are often overlooked in the management of these patients. The aim: is to assess the sexual health of patients with NPC at different stages of their treatment.
Methods
This is a descriptive analytical study evaluating sexual health in adult patients with NPC using EORTC SHQ-C22 Questionnaire. Thirty married patients were included between September and December 2023. The mean age was 45 years [32-68] with a sex ratio of 4 (24/6). Tumor stage (III) was the most represented (25 patients; 83.3%). The questionnaire was translated into colloquial Arabic and administered during treatment for 27 patients (71.4%), and within the first 6 months of follow-up for 3 patients. All patients resided at home with their spouses at the time of the questionnaire.
Results
According to the EORTC SHQ-C22 scale, 17 patients were not sexually active (not at all or a little) during treatment (56.6%) with a feeling of sexual satisfaction (often or quite often) in 17 patients (70.8%). Thirteen patients (43.3%) considered sexual activity to be enjoyable (often or quite often). A negative impact of fatigue and treatment on sexual activity was experienced by 14 patients (46.6%, often or quite often) and a feeling of inability to satisfy their partner was felt by 12 patients (7% a little, 10% often, and 73% quite often). Sexual activity was not painful for 26 patients (86.6%), and concerns about pain during sexual intercourse or intimate physical contact were not felt by 21 patients (70%). Discussion with a doctor about sexuality was absent in most cases (27 patients, 90%). Communication with the partner about sexuality was unsatisfactory in all patients (90% did not communicate and 10% communicated very little). The median score of the EORTC SHQ-C22 was 67 [30-75]. Among these patients, 7 patients (23.3%) wished to receive treatment for their sexuality, and no patient was using any specific sexual treatment.
Conclusions
The search for sexual disorders in patients with NPC is essential, for better quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut National d'Oncologie Rabat.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11